Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis
Liver International · 2025-04 · 45 (4)
DOI: 10.1111/liv.16186 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 28.11.2024. Verfasst von Daniel Lindén und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, S…. Hauptthemen laut MEDLINE: Membrane Proteins, Liver Cirrhosis, Lipase, Fatty Liver. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is caused by metabolic triggers and genetic predisposition. Among the genetic MASLD risk variants identified today, the common PNPLA3 148M variant exerts the largest effect size of MASLD heritability. The PNPLA3 148M protein is causatively linked to the development of liver steatosis, inflammation and fibrosis in experimental studies and is therefore an appealing target for therapeutic approaches to treat this disease. Several PNPLA3 targeted approaches are currently being evaluated in clinical trials for the treatment of metabolic dysfunction‐associated steatohepatitis (MASH), the most severe form of MASLD and promising proof of principle data with reduced liver fat content in homozygous PNPLA3 148M risk allele carriers has been reported from phase 1 trials following hepatic silencing of PNPLA3 . Thus, targeting PNPLA3, the strongest genetic determinant of MASH may hold promise as the first precision medicine for the treatment of this disease. A histological endpoint‐based phase 2b study has been initiated and several more are expected to be initiated to evaluate treatment effects on histological MASH and liver fibrosis in participants being homozygous for the PNPLA3 148M risk allele variant. The scope of this mini‐review is to briefly describe the PNPLA3 148M genetics, function and preclinical experimental evidence with therapeutic approaches targeting PNPLA3 as well as to summarise the PNPLA3 based therapies currently in clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Division of Endocrinology, Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- Internal Medicine Research Unit, Discovery & Early Development, Pfizer Inc., Cambridge, Massachusetts, USA.
- MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, La Jolla, California, USA.
ORCID-Profile: Daniel Lindén, Gregory Tesz, Rohit Loomba
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- NIAAA NIH HHS
- John C Martin Foundation
- NHLBI NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Alcohol Abuse and Alcoholism
- National Heart, Lung, and Blood Institute
Zitieren
APA
Lindén, D., Tesz, G., & Loomba, R. (2025). Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis. Liver International, 45(4). https://doi.org/10.1111/liv.16186
Vancouver
Lindén D, Tesz G, Loomba R. Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis. Liver International. 2025;45(4). doi:10.1111/liv.16186
BibTeX
@article{Lindn2025,
author = {Lindén, Daniel and Tesz, Gregory and Loomba, Rohit},
title = {Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis},
journal = {Liver International},
year = {2025},
volume = {45},
number = {4},
doi = {10.1111/liv.16186}
}
EUVIMED